Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
PDL BioPharma, Inc. |
---|---|
Information provided by: | PDL BioPharma, Inc. |
ClinicalTrials.gov Identifier: | NCT00528827 |
To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Cardene® I.V. |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension |
Estimated Enrollment: | 140 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator |
Drug: Cardene® I.V.
|
2: Experimental
5 mcg
|
Drug: Cardene® I.V.
|
3: Experimental
2.5
|
Drug: Cardene® I.V.
|
4: Experimental
0.5
|
Drug: Cardene® I.V.
|
Children with acute hypertensive episodes are frequently treated with the same marketed drugs as adults. Few drugs are specifically indicated for use in children with severe hypertension. Cardene I.V. has been widely used in children with severe hypertension without specific dosing recommendations for children in the labeling. This study is designed to examine the pharmacokinetics, pharmacodynamics, safety, and efficacy of using Cardene I.V. to reduce blood pressure (BP) in children with hypertension and will provide important information to guide use in pediatric patients.
Ages Eligible for Study: | 2 Years to 16 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Females who meet either of the following criteria:
Non-childbearing potential , as documented by:
Exclusion Criteria:
Responsible Party: | None for this trial ( None for this trial ) |
Study ID Numbers: | Cardene® I.V. 1406 |
Study First Received: | September 10, 2007 |
Last Updated: | August 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00528827 |
Health Authority: | United States: Food and Drug Administration |
Hypertension, High Blood Pressure, Pediatric Hypertension, High blood pressure in children |
Calcium, Dietary Vascular Diseases Nicardipine Hypertension |
Membrane Transport Modulators Vasodilator Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Calcium Channel Blockers |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |